- Home
- GALT vs REGCO Comparison
GALT vs REGCO Comparison
Compare GALT & REGCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GALT
- REGCO
- Stock Information
- Founded
- GALT 2000
- REGCO N/A
- Country
- GALT United States
- REGCO United States
- Employees
- GALT N/A
- REGCO 497
- Industry
- GALT Biotechnology: Pharmaceutical Preparations
- REGCO
- Sector
- GALT Health Care
- REGCO
- Exchange
- GALT Nasdaq
- REGCO Nasdaq
- Market Cap
- GALT 147.8M
- REGCO N/A
- IPO Year
- GALT N/A
- REGCO N/A
- Fundamental
- Price
- GALT $1.04
- REGCO $22.31
- Analyst Decision
- GALT Strong Buy
- REGCO
- Analyst Count
- GALT 1
- REGCO 0
- Target Price
- GALT $11.00
- REGCO N/A
- AVG Volume (30 Days)
- GALT 1.1M
- REGCO N/A
- Earning Date
- GALT 11-13-2024
- REGCO N/A
- Dividend Yield
- GALT N/A
- REGCO N/A
- EPS Growth
- GALT N/A
- REGCO N/A
- EPS
- GALT N/A
- REGCO N/A
- Revenue
- GALT N/A
- REGCO N/A
- Revenue This Year
- GALT N/A
- REGCO N/A
- Revenue Next Year
- GALT N/A
- REGCO N/A
- P/E Ratio
- GALT N/A
- REGCO N/A
- Revenue Growth
- GALT N/A
- REGCO N/A
- 52 Week Low
- GALT $0.73
- REGCO N/A
- 52 Week High
- GALT $4.27
- REGCO N/A
- Technical
- Relative Strength Index (RSI)
- GALT 20.80
- REGCO 28.91
- Support Level
- GALT $1.80
- REGCO $22.25
- Resistance Level
- GALT $2.36
- REGCO $22.50
- Average True Range (ATR)
- GALT 0.27
- REGCO 0.26
- MACD
- GALT -0.08
- REGCO -0.03
- Stochastic Oscillator
- GALT 15.07
- REGCO 19.93
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
About REGCO Regency Centers Corporation 5.875% Series B Cumulative Redeemable Preferred Stock
Regency Centers is one of the largest shopping center-focused retail REITs. The company's portfolio includes an interest in 483 properties, which includes over 57 million square feet of retail space following the completion of the Urstadt Biddle acquisition in August 2023. The portfolio is geographically diversified with 22 regional offices and no single market representing more than 12% of total company net operating income. Regency's retail portfolio is primarily composed of grocery-anchored centers, with 80% of properties featuring a grocery anchor and grocery stores representing 20% of annual base rent.